NASDAQ: CVRXCvrx Inc Stock
$5.86-0.07 (-1.18%)
Updated Jun 13, 2025
CVRX Price
$5.86
Fair Value Price
N/A
Market Cap
$152.79M
52 Week Low
$4.30
52 Week High
$18.55
P/E
-2.73x
P/B
2.2x
P/S
5.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$52.87M
Earnings
-$51.55M
Gross Margin
83.4%
Operating Margin
-88.21%
Profit Margin
-97.5%
Debt to Equity
0.87
Operating Cash Flow
-$41M
Beta
1.55
Next Earnings
Jul 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CVRX Overview
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for patients with cardiovascular diseases. Its lead product, Barostim, is a pacemker-like device that improves symptoms for patients who have suffered heart failure. CVRx was incorporated in 2000 and is headquartered in Minneapolis, MN.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CVRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
CVRX
Ranked#90 of 108
Ranked#90 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.39 | A | |
| $12.10 | A | |
| $20.07 | A |
Be the first to know about important CVRX news, forecast changes, insider trades & much more!
CVRX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CVRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CVRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CVRX is good value based on its book value relative to its share price (2.2x), compared to the US Medical Devices industry average (3.99x)
P/B vs Industry Valuation
CVRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CVRX due diligence checks available for Premium users.
Valuation
CVRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.73x
Industry
35.6x
Market
31.36x
CVRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.2x
Industry
3.99x
CVRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CVRX's financial health
Profit margin
Revenue
$12.3M
Net Income
-$13.8M
Profit Margin
-111.5%
CVRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CVRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$129.6M
Liabilities
$60.2M
Debt to equity
0.87
CVRX's short-term assets ($126.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVRX's short-term assets ($126.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.8M
Investing
-$114.0k
Financing
$9.6M
CVRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CVRX vs Medical Device Stocks
Cvrx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.